CGEN Stock — Compugen Ltd.: Cash, EV, Pipeline

Share price

$2.49

Market cap

$235.5M

Cash

$99.9M

Enterprise value

$135.6M

Balance sheet

Cash	$99.9M
Debt	$0.0M
Net cash	$99.9M
Enterprise value	$135.6M
Basic shares	94.6M shares
Fully diluted shares	104.5M shares
Fully diluted market cap	$260.1M
Cash per share	$1.06

Cash figures as of 2025-12-31. Database snapshot: 2026-09-21.

Price history

Loading CGEN daily closes…

Loading price history…

Upcoming catalysts

Expected	Drug	Phase	Indication	Mgmt guide
Apr 12 - May 24	COM701	Phase 2	Ovarian Cancer; Ovarian Cancer Recurrent	Q1 2027
Jan 3 - Feb 14	COM503	Phase 1	Neoplasm; Cancer, Malignant Tumors	—

Estimated readout windows: registry primary-completion date + 6-12 weeks. Windows already open are shown from "Now". Drug names link to ClinicalTrials.gov.

Full readout calendar →

Pipeline assets

rilvegostomig

Phase 3 · Active Modality: bispecific antibody

Target PD-1 / TIGIT

Partnerships AstraZeneca (exclusive license, as amended December 16, 2025, to use Compugen's monospecific anti-TIGIT antibodies including COM902 for development of bi-specific and multi-specific antibody products; AstraZeneca developed rilvegostomig and is evaluating it)

Indications

Not disclosed (Phase 3)

Status note PD-1/TIGIT bi-specific antibody with a TIGIT component derived from COM902. Being evaluated by AstraZeneca in multiple Phase 3, Phase 2 and Phase 1 clinical trials. Filing notes recent failures in the TIGIT field (including discontinuation of the Phase 3 STAR-221 domvanalimab-based combination in upper GI cancers in December 2025 due to futility).

COM701

Phase 1 · Active Modality: monoclonal antibody

Target PVRIG

Indications

Solid tumors (Phase 1)
Relapsed platinum-sensitive ovarian cancer (maintenance) (Stage not disclosed)

Status note Anti-PVRIG antibody. Phase 1 trials conducted as monotherapy, in combination with nivolumab, and in triplet combinations. Currently conducting the MAIA-ovarian platform trial evaluating COM701 as a single agent in maintenance therapy in relapsed platinum-sensitive ovarian cancer.

COM902

Phase 1 · Active Modality: monoclonal antibody

Target TIGIT

Indications

Solid tumors (Phase 1)

Status note Therapeutic anti-TIGIT antibody evaluated in a Phase 1 dose escalation monotherapy trial. Based on negative data in the TIGIT field, the company currently believes COM902 has limited near-term value potential and does not plan to initiate new clinical trials with it; the decision may be revisited pending further TIGIT data from other companies.

GS-0321

Phase 1 · Active Modality: monoclonal antibody

Aliases COM503

Target IL-18 binding protein (IL-18 pathway)

Partnerships Gilead (exclusive license to the preclinical anti-IL-18 binding protein antibody program, December 2023; Compugen is responsible for conducting a Phase 1 clinical trial of GS-0321 including regulatory matters)

Indications

Not disclosed (Phase 1)

Status note Antibody targeting the IL-18 pathway. Licensed to Gilead; currently being evaluated in a Phase 1 clinical trial that Compugen sponsors and conducts. Compugen is responsible only for Phase 1 clinical development.

Per-asset detail extracted from the 20-F filed 2026-03-02. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.

Pipeline

Lead drug	COM701
Lead indication	Ovarian Cancer
Lead phase	Phase 2
Active trials	2

Active clinical trials

Trial	Phase	Status	Role	Sponsor	BP	Condition(s)	Mgmt guide
NCT06888921	Phase 2	Recruiting	Sponsor	CGEN	—	Ovarian Cancer; Ovarian Cancer Recurrent	Q1 2027
NCT06759649	Phase 1	Recruiting	Sponsor	CGEN	GILD	Neoplasm; Cancer, Malignant Tumors	—

Sponsor-matched active trials from ClinicalTrials.gov (2 as sponsor, 0 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.

View all 2 active trials for Compugen Ltd on ClinicalTrials.gov

No specialist-fund holders in 13F data for this company.

CGEN — Compugen Ltd.

Balance sheet

Price history

Upcoming catalysts

Pipeline assets

Pipeline

Active clinical trials